anxiolytic/vomiting

Authors evaluated two forms of antiemetic therapy in 129 courses of 51 gynecological cancer patients treated with cisplatin chemotherapy of moderately or highly emetic dose (50-100 mg/m2) in a prospective, non randomized study. The patients received granisetron (3 mg, intravenously) and

Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy. Cisplatin induces anticipatory and acute, as well as, delayed emesis. High doses of metoclopramide can effectively decrease the intensity of these symptoms in up to 70% of cases. Several

BACKGROUND Several drugs and techniques have been used to reduce the incidence of postoperative nausea and vomiting (PONV). However PONV continues to be a common postoperative complication. Midazolam premedication in pediatric patients has been reported to reduce the incidence of PONV. In the

Vomiting was suppressed in cats pretreated with 8-OH-DPAT and then challenged with an emetic stimulus; motion, xylazine or cisplatin. The antiemetic effect is likely due to stimulation of postsynaptic serotonin-1A receptors. The most parsimonious explanation is that it acts at a convergent

The availability of radiolabelled ligands selective for various putative neurotransmitter receptor sites and the development of quantitative autoradiography has led to a greater understanding of the neuronal pathway and receptor subtypes involved in the vomiting reflex induced by various mechanisms

BACKGROUND A 51-year-old woman experienced refractory chemotherapy-induced nausea and vomiting (CINV) in spite of extensive antiemetic therapy, including 5-HT3 antagonists, corticosteroids, dopamine antagonists and antihistamines. METHODS We administered the patient clonazepam. After taking

Cannabis is commonly used in cyclic vomiting syndrome (CVS) due to its antiemetic and anxiolytic properties. Paradoxically, chronic cannabis use in the context of cyclic vomiting has led to the recognition of a putative new disorder called cannabinoid hyperemesis syndrome (CHS). Since its first

BACKGROUND The prehospital treatment of pain and discomfort among patients who suffer from acute coronary syndrome (ACS) needs a treatment strategy which combines relief of pain with relief of anxiety. OBJECTIVE The aim of the present study was to evaluate the impact on pain and anxiety of the

Emetophobia is an intense, irrational fear of vomiting including fear of feeling nausea, seeing or hearing another person vomit, or seeing vomitus itself. It may occur at any age and we need to understand its symptomatology. We report a case of emetophobic child whose fear of vomiting started after

Usefulness of alprazolam for control of chemotherapy-induced emesis including 5-day continuous intravenous infusion of cisplatin for advanced lung cancer was evaluated by a randomized crossover design. Of 22 cases evaluated, 8 in the alprazolam group and 1 in the untreated group were free from

BACKGROUND We conducted a nationwide survey on chemotherapy-induced nausea and vomiting (CINV) in Japan and demonstrated good compliance with Japanese CINV guidelines, resulting in good control of vomiting. However, almost half the patients experienced breakthrough CINV. We analyzed the survey

The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated

For the last century, empiric therapy has been used to treat the relentless vomiting and resulting dehydration associated with cyclic vomiting syndrome. Despite its unknown pathogenesis, in the last decade, uncontrolled trials of various antimigraine and antiemetic agents have demonstrated rates of

The novel atypical antipsychotic ziprasidone has a pharmacologic profile notable for potent agonism of serotonin (5-HT)1A receptors, antagonism at 5-HT1D receptors, and reuptake inhibition of norepinephrine. 5-HT1A receptor agonism, in particular, suggests anxiolytic activity, and ziprasidone has

OBJECTIVE Despite significant advances in antiemetic management, almost 50% of cancer patients still experience nausea and vomiting during treatment. The goal of antiemetic therapy is complete prevention of treatment-induced nausea and/or vomiting (TINV); however, realisation of this goal remains